PT-141 (Bremelanotide)

Melanocortin receptor agonist (MC3R/MC4R) used for sexual desire and arousal.

Quick Reference

Dose: 0.5–1.75 mg
Frequency / schedule: As needed
Route: Subcutaneous
Timing: 45 minutes before anticipated activity
Fasting: Not required (light meal may help nausea)
Cycle: As needed (max 1 dose/24 h, ≤8 doses/month recommended)
Time off: Do not exceed frequency limits
Common vial strengths: 10 mg research vials

How this works

PT-141 activates melanocortin receptors (primarily MC4R and MC3R) in the central nervous system, increasing sexual desire and arousal through pathways distinct from vascular agents like PDE5 inhibitors.

Benefits + side effects

Potential Benefits

Increased sexual desire and arousal

Side Effects

Nausea (very common, ~40% at full dose)
Flushing, headache, injection-site reactions
Transient blood-pressure increase
Possible focal hyperpigmentation with frequent use

Dosing / Protocol

Reference Protocol

Phase / week	Dose	Frequency	Timing	Notes
Test / Start	0.5–1.0 mg	First use	45 min before activity	Assess nausea tolerance
Standard	1.0–1.75 mg	As needed (≤1/24 h)	45 min before activity	Full range

Timing + Fasting Notes

Inject approximately 45 minutes before anticipated sexual activity. Light meal beforehand may reduce nausea. Do not exceed one dose in 24 hours.

Reconstitution

Common vial strengths10 mg research vials

Approved preparation example
Calculate for easy units at desired dose.

Practical Reference

Storage: Refrigerated reconstituted
Route / injection context: Subcutaneous
Common vial strengths: 10 mg research vials
Cycle / time off: As needed (max 1 dose/24 h, ≤8 doses/month recommended) · Do not exceed frequency limits
Practical notes: Nausea is the main limiting factor — start low. Research use.

References

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsObstetrics & Gynecology · 2019

CLINICAL TRIAL

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.

Search Femetric